Trav21: A Potential Drug Target for Cancer (G28662)

Target Name: TRAV21

NCBI ID: G28662

TRAV21

Other Name(s): TCRAV23S1 | TVA21_HUMAN | T cell receptor alpha variable 21 | TCRAV21S1

Trav21: A Potential Drug Target for Cancer

Trav21 (T-cell receptor activator 21) is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, kidneys, and gastrointestinal tract. It is a member of the T-cell receptor family, which is a crucial signaling pathway in the immune system. Trav21 plays a crucial role in the regulation of immune responses and is involved in the development of various diseases, including cancer.

Recent studies have identified Trav21 as a potential drug target for the treatment of various diseases, including cancer. One of the main reasons for its potential as a drug is its involvement in the regulation of immune responses. Trav21 has been shown to play a role in the regulation of T-cell responses, which are critical for the immune system's ability to fight off infections and cancer.

One of the most promising aspects of Trav21 as a drug target is its potential to specifically target cancer cells, rather than healthy cells. This is because Trav21 is known to be expressed in various types of cancer cells, but not in healthy cells. This allows for the potential to specifically target cancer cells and reduce the risk of unintended side effects.

Another potential benefit of Trav21 as a drug target is its potential to be used in combination with other treatments. This is because Trav21 has been shown to work well with other drugs, such as chemotherapy and radiation therapy, which are often used in the treatment of cancer. By using Trav21 in combination with these other treatments, doctors may be able to provide more effective and less toxic treatments to patients.

Trav21 has also been shown to have potential as a biomarker for the diagnosis and monitoring of various diseases, including cancer. This is because Trav21 is often expressed in the immune cells that are affected by the disease, which allows for its potential to be used as a marker for the disease. This can be important for early detection and monitoring of diseases, as well as for evaluating the effectiveness of different treatments.

In conclusion, Trav21 is a protein that has shown potential as a drug target for the treatment of various diseases, including cancer. Its involvement in the regulation of immune responses makes it an attractive target for drug development, and its potential to specifically target cancer cells and be used in combination with other treatments makes it an promising addition to the treatment options available for various diseases. Further research is needed to fully understand the potential of Trav21 as a drug and to determine its safety and effectiveness in clinical trials.

Protein Name: T Cell Receptor Alpha Variable 21

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets